Ken Griffin Cytosorbents Corp Call Options Transaction History

Citadel Advisors LLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$0.7 - $1.55 $3,709 - $8,215	5,300 Added 52.48%	15,400 $23,000
Q2 2024 Aug 14, 2024	BUY	$0.7 - $1.01 $7,070 - $10,201	10,100 New	10,100 $7,000
Q3 2023 Nov 14, 2023	SELL	$1.86 - $4.03 $25,854 - $56,017	-13,900 Reduced 86.34%	2,200 $4,000
Q2 2023 Aug 14, 2023	BUY	$2.37 - $3.65 $2,133 - $3,285	900 Added 5.92%	16,100 $57,000
Q1 2023 May 15, 2023	BUY	$1.79 - $4.17 $27,208 - $63,384	15,200 New	15,200 $51,000

16.7M

15.4K

Ticker CTSO
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 43,577,400
Market Cap $42.3M
Description
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunct...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.